Kynurenine Assay to Detect Inflammation in Transplant Patient: Clinical Results
1Center of Surgery, University of Ulm, Ulm, Germany
2Renal Transplant Center, Municipal Friedrichshain Hospital, Berlin, Germany
3General, Visceral and Transplant Surgery, Ludwig-Maximilians-Universität, München, Munich, Germany.
Meeting: 2015 American Transplant Congress
Abstract number: 455
Keywords: Inflammation, Kidney transplantation, Monitoring, Rejection
Session Information
Session Name: Concurrent Session: Kidney: Acute Cellular Rejection
Session Type: Concurrent Session
Date: Tuesday, May 5, 2015
Session Time: 4:00pm-5:30pm
Presentation Time: 4:12pm-4:24pm
Location: Room 121-AB
Introduction: Ideal biomarker should be specific, sensitive, non-invasive, mirror the benefit of therapy and offer prognostic potential. We developed a test using a colorimetric assay to detect kynurenine (Kyn) changes in patients. Kynurenine [EC 1.13.11.42] is generated downstream in the tryptophan metabolism and one of the key players concerning inflammatory response and known for immune-modulation not only on T-regulatory and NK cells.
Materials and Methods: Blood samples were measured retrospectively from 355 renal transplant patients (n=4600) and prospectively from 104 patients (n=790). 292 healthy blood donors served as normal controls. We then developed a test method in saliva of the patients first on basis of the colorimetric assay including the normal controls and 66 (n=290) patients after renal transplantation with 18 rejection episodes.
Results: Test-recovery rate was 97-99,8%, intra-assay variance 1,53% and inter-assay variance 2,77%. Values in normal controls were 2,7+0,4 ¯o;M for serum and 0,9+0,4¯o;M for saliva. Mean values in patients with rejection (BPAR) was 17,4+8,4 ¯o;M in serum (s) and 4,6+1,6 ¯o;M in saliva (sal) compared to uneventful patients 4,3+1,6 ¯o;M (s) and 1,3+0,6¯o;M (sal). The proportion rate was equal between normal controls, uneventful patients after transplantation and rejection. We found a) a significant correlation of Kyn and rejection episodes (BPAR) early in the beginning, b) a predictive information concerning the long-term run of the transplant (up to 144 mos) and c) excellent tool for monitoring therapeutic interventions. In serum testing we could differentiate significant between steroid-sensitive, steroid-resistant and antibody mediated rejection and infection. In saliva we found no circadian behavior.
Conclusion: This test fulfills the given prerequisites. It is a safe and reliable method, is easy and quick to perform and not costly. Further validation is planned in prospective clinical observational and interventional studies.
To cite this abstract in AMA style:
Abendroth D, Kaden J, Marzinzig M, Stangl M. Kynurenine Assay to Detect Inflammation in Transplant Patient: Clinical Results [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/kynurenine-assay-to-detect-inflammation-in-transplant-patient-clinical-results/. Accessed May 11, 2025.« Back to 2015 American Transplant Congress